A generic alternative indicated for Heart and Blood Pressure. This formulation supports the management of blood clotting risks to promote healthier cardiovascular circulation.
Utilized to manage blood clotting risks by addressing coagulation proteins to alleviate stroke danger and mitigate the recurrence of venous thromboembolism in adults.
Mechanism of Action
Apixaban selectively inhibits Factor Xa, a vital protein for blood clotting. By stopping this factor, the drug prevents the conversion of prothrombin to thrombin, thereby inhibiting the formation of a physical blood clot.
Route of Administration
Oral
Onset Time
3–4 hours
Duration
12–24 hours
Contraindications
Active major bleeding, Severe renal failure, Hypersensitivity to apixaban, Mechanical heart valves
Information for Eliquis is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
